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Conclusion: Patients with thrombophilic abnormalities and venous
thromboembolism (VTE) have an increased risk of recurrence of VTE.
Summary: The authors studied the recurrence of VTE in patients with
andwithout thrombophilic abnormalities whowere treated with a standardized
anticoagulation program. The analysis was from a prospective, multicenter,
randomized study evaluating clinical benefit of 1 year of oral anticoagulant
treatment vs a 3-month period of oral anticoagulant treatment after a first
episode of idiopathic proximal deep vein thrombosis. Patients were screened for
protein C and protein S deficiencies, antithrombin, hyperhomocysteinemia,
antiphospholipid antibodies,mutation 20210GAof the prothrombin gene, and
resistance to activated protein C, Factor-5/R506Q mutation, or both. VTE
recurrence was documented by objective testing with ultrasound imaging or
catheter-based techniques. An independent committee unaware of the results of
thrombophilia screening adjudicated all recurrences.
Screening for thrombophilic abnormalities was done in 195 patients.
Of 57 patients with detected thrombophilic abnormalities, 20 (35.1%)
experienced VTE recurrence compared with 29 (21.0%)of 138 patients
without thrombophilia (hazard ratio, 1.78; 95% confidence interval, 1.02 to
3.14; P  .046). Differences in VTE recurrence between patients with and
without thrombophilia can be accounted for by patients who received only
3 months of oral anticoagulation (hazard ratio, 3.21; 95% confidence
interval, 1.349 to 7.616; P  .008).
Comment: Like others before it, this study suggests longer durations
of treatment for patients with idiopathic VTE. This study has too few
patients to allow precise recommendations for duration of therapy on the
basis of the thrombophilic abnormality identified. Nevertheless, it is now
quite clear that not all VTE is the same. Patients with thrombophilia should
be considered at higher risk of recurrence and probably treated with warfarin
for at least 1year after their initial VTE event.
The insensate foot following severe lower extremity trauma: An indi-
cation for amputation?
BosseMJ,McCarthyML, Jones AL, et al, and the Lower Extremity Assessment
Project (LEAP) Study Group. J Bone Joint Surg 2005;86A:2601-8.
Conclusion: Insensation of the plantar surface of the foot after lower
extremity trauma is not prognostic of long-term plantar sensory status or
functional outcome. More than half of patients who presented with an
insensate foot after lower extremity trauma ultimately regained sensation at
2 years. Assessment of plantar sensation should not be a component of the
limb salvage decision algorithm.
Summary: Evaluation of plantar sensation is routine in the assessment
of the impact of lower extremity trauma. The authors sought to determine
long-term outcome after treatment of severe lower extremity trauma in
patients who presented with absent plantar sensation. There were 55 sub-
jects with an insensate extremity at the time of presentation, of whom 26
underwent amputation and 29 were treated for limb salvage. Also included
was a control group consisting of patients with lower extremity trauma with
intact plantar sensation at presentation who underwent limb reconstruction.
Injury characteristics and functional and health-related quality-of-life out-
comes at 1 and 2years after injury were compared in the three groups.
The insensate salvage group did not have a reported or demonstrated
worse outcome at 1 or 2 years compared with the insensate amputation or
sensate control groups. Approximately 55% of patients in both the insensate
salvage and sensate control groups in whom the limb was salvaged had
normal plantar sensation at 2 years after injury. This was regardless of
whether plantar sensation had been reported to be intact at the time of
presentation after injury. No differences were noted in overall physical or
psychosocial scores in the three groups. At 2 years after injury, only one
patient in the insensate salvage group had absent plantar sensation.
Comment: The data suggest assessment of plantar sensation after
lower extremity trauma is essentially worthless in predicting the ultimate
sensory status of the foot. These study findings do not support the wide-
spread belief that absent initial plantar sensation in patients with a leg-
threatening injury correlates with poor long-term outcome if the limb were
to be salvaged. This study implies that tibial nerve dysfunction at the time of
presentation does not necessarily imply transaction of the tibial nerve. It is
important to remember that reversible ischemic injuries to nerves as well as
neurapraxic injuries of peripheral nerves may mimic permanent loss of
peripheral nerve function.
Association between carotid plaque characteristics and subsequent
ischemic cerebrovascular events: A prospective assessment with MRI—
initial results
Takaya N, Yuan C, Chu B, et al. Stroke 2006;37:818-23.Conclusion: In patients with 50% to 79% asymptomatic internal ca-
rotid artery stenosis, magnetic resonance imaging (MRI) can identify plaque
characteristics predictive of future cerebral vascular events.
Summary: Previous studies indicate it is possible to quantify plaque
size and composition withMRI. The authors tested the hypothesis thatMRI
assessment of asymptomatic carotid plaque is predictive of future ipsilateral
cerebrovascular events.
The study enrolled 154 consecutive patients with asymptomatic 50% to
79% internal carotid artery stenosis as determined by ultrasound imaging. All
patients had 12 months of follow-up. All underwent multicontrast-
weighted carotid MRIs at baseline. Study subjects were subsequently fol-
lowed up every 3 months and assessed for occurrence of symptomatic
cerebrovascular events. Mean follow-up was 38.2 months. Cerebrovascular
events were defined as stroke or transient ischemic attack in the regions
supplied by the index carotid artery or the occurrence of ipsilateral amaurosis
fugax. Only the events related to the index artery were considered.
There were 12 carotid cerebrovascular events ipsilateral to the index
carotid artery. Two patients with events secondary to atrial fibrillation were
excluded. Cox regression analysis demonstrated a relationship between
subsequent neurologic events and the following plaque characteristics:
presence of a ruptured or thin fibrous cap (hazard ratio [HR], 17.0; P 
.001), intraplaque hemorrhage (HR, 5.2; P  .005), increased mean in-
traplaque hemorrhage area (HR for 10 mm2 increase, 2.6; P .006), larger
maximum percent lipid-rich/necrotic core (HR for each 10% increase, 1.6;
P  .004), and increased maximum wall thickness (HR for each 1-mm
increase, 1.6; P  .008).
Comment: Papers such as this represent the second phase of determin-
ing which patients with asymptomatic carotid plaques will most likely benefit
from prophylactic carotid endarterectomy. Initial studies were all retrospec-
tive. Prospective studies such as this are now appearing. The data are
extremely interesting and potentially highly clinically significant if in larger
multicenter studies validated measurements of plaque characteristic can
eventually be used to predict the patient with asymptomatic carotid stenosis
who is truly at risk for an ipsilateral neurologic event.
Population-based study of event-rate, incidence, case fatality, and
mortality for all acute vascular events in all arterial territories (Oxford
Vascular Study)
Rothwell PN, Coull AJ, Silver LE, et al for the Oxford Vascular Study.
Lancet 2005;366:1773-83.
Conclusion: Even outside of the coronary circulation, there is a high
rate of acute vascular events that increases steeply with age.
Summary: Vascular events involving the coronary, cerebrovascular,
and peripheral circulations have common risk factors, pathology, and pre-
ventative treatments. These multiple circulatory beds are rarely studied
concurrently, however. In this study, the authors compared the incidence of
acute vascular events in the coronary, cerebrovascular, and peripheral terri-
tories and related these events to aging of the population. This was a
prospective study of data collected between 2002 and 2005 assessing 9106
individuals in Oxfordshire, United Kingdom, for an acute vascular event of
any type.
There were 2,004 acute vascular events in 1,657 individuals. There
were 918 cerebrovascular events (45%), of which 618 were stroke, and 300
were transient ischemic attack. There were 856 coronary events (42%), of
which 316 were non-ST elevation myocardial infarction, 159 were ST
elevation myocardial infarction, 218 were unstable angina, and 163 were
sudden cardiac death. Nine percent of the acute vascular events were
peripheral vascular events (n  188). These included 92 episodes of critical
limb ischemia, 53 episodes of visceral or limb ischemia secondary to emboli,
and 43 aortic events. There were also 62 unclassifiable deaths.
Compared with coronary events, the relative incidence of cerebrovas-
cular events was 1.19 (95% confidence interval [CI], 1.06 to 1.13). For
nonfatal cerebrovascular events, the relative incidence compared with coro-
nary events was 1.40 (95% CI, 1.23 to 1.59). If transient ischemic attacks
and unstable angina were excluded, the relative incidence of cerebrovascular
events to coronary events was 1.21 (95% CI, 1.04 to 1.41). A steep rise
occurred in the incidence of vascular events in all territories with age. Case
fatality rates increased with age, and 47% of the 1561 nonfatal events
occurred at age 75 years.
Comment: There is nothing particularly surprising in this study except
that perhaps cerebrovascular events were more common than coronary
events. It is also interesting that half of all events occurred in patients 75
years. The age distribution of vascular events suggests that trials designed to
assess interventions for atherosclerotic vascular disease must include a large
proportion of older patients. Limiting studies to patients 80 years, as is
frequently done, will exclude that segment of the population with the largest
number of events.
